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Abstract
Stent thrombosis is an uncommon but serious complication that causes sudden death 
or myocardial infarction (MI). A large MI, especially with ST elevation, can cause car-
diogenic shock and pose a significant incidence of morbidity and mortality. Largeness 
of ischemic territory is the main reason that causes cardiogenic shock. The fundamental 
treatment strategies are immediate coronary revascularization and perfusion support to 
avoid end organ damage with medically or mechanical in intensive care units. The pre-
vention, incidences, mechanisms, management, and clinical impacts of cardiogenic shock 
discussed under this topic.
Keywords: cardiogenic shock, stent thrombosis, drug-eluting stent, bare-metal stent, 
bioabsorbable stent, treatment
1. Introduction
1.1. Stent thrombosis: incidence, pathophysiological mechanisms, technological 
developments
Percutaneous coronary interventions are the main treatment of coronary artery disease 
patients with target vessel stenting. In 1977, firstly, it was performed by Andreas Gruntzig; 
afterward in 1994, the Food and Drug Administration (FDA) approved the procedure. 
Nowadays, coronary stent use is more than 90% of the percutaneous coronary interventions. 
Since the start of revascularization of coronary arteries with percutaneous transluminal coro-
nary angioplasty (PTCA), invasive cardiologists face with a fatal problem, stent thrombosis. 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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Today, invasive cardiologists have a lot of options between bare metal stents (BMSs), first and 
second generation of drug-eluting stents (DESs) and bioresorbable vascular stents (BVSs). 
The decision of which kind of stent is up to physicians and particular factors about patient 
and his/her clinics have an effect on the choice. Widespread use of stents for target vessel 
revascularization brings the problem of different rates of restenosis which has a percutaneous 
reintervention necessity [1]. The neo-endothelial coverage with proliferation and migration of 
vascular smooth muscle and proteoglycan deposition causes restenosis. Restenosis may occur 
mostly within the first 6–9 months after implantation, depending on type of strut and proce-
dure. Drug released from DES inhibits the signal transduction pathways of proliferation of 
vascular smooth muscle cell and migration. DES delays reendothelialization and avoid from 
prothrombogenic events.
Bare metal stent implantation reduces the risk of restenosis more than 50% when compared 
to balloon angioplasty. However, BMS has still a risk of 20–30% restenosis in the following 
year after implantation. Restenosis mostly occurs in diabetic patients, small vessels, and long 
lesions. Currently, BMSs often used in shortening dual antiplatelet time after implantation. 
DES significantly reduces restenosis compared to BMS [2].
Stent thrombosis is the acute, completely thrombotic occlusion of the stented segment of coro-
nary artery. The incidence has been reported in various studies about 0.5–2% for elective cases 
and up to 6% for the patients presented with acute coronary syndromes underwent PCI. Stent 
thrombosis causes ST elevation myocardial infarction (MI) in 70–80% cases. Major clinical 
impacts, high mortality rates, nearly 40%, make the issue nightmare of interventional cardiol-
ogists [3]. Stent thrombosis alters by the time event occurs with different mechanisms. Mostly, 
stent thrombosis occurs within 30 days after placement. Acute stent thrombosis becomes in 24 h, 
if any thrombosis occurs between 24 h and 30 days, defined as early stent thrombosis. These 
are arising from mechanical issues, failure of platelet adhesion aggregation suppression, per-
sistence of slow coronary flow and prothrombotic constituents. Late stent thrombosis (up to 
1 year) and very late stent thrombosis (after the first year) are results of delayed reendothelial-
ization and neointimal coverage. Delay of neointimal restoration and ongoing vascular repair 
is particularly the effects of agents used in DES to prevent proliferation [4].
The first generation of DES, paclitaxel and sirolimus eluting stents, has an increased risk of 
late and very late stent thrombosis, as compared to BMS caused more delayed reendotheli-
alization, impaired arterial healing and long lasting inflammation. However, in newer gen-
eration of DES, late stent thrombosis risks are similar with BMS, lower than first generation. 
Signalizations of inflammatory and thrombotic pathways are similar, and inflammation acti-
vates clotting cascade and enhances the platelet activation [5].
Binding of von Willebrand’s factor with factor VIII, glycoproteins Ib and Ia/IIb and collagen 
assures platelet adhesion to stent struts. Platelets provide aggregation by glycoproteins Ib, 
IIb/IIIa, serotonin, and fibrinogen causes thrombosis. BMS thrombosis mostly occurs within 
the first 24 h after stent implantation, less often within 30 days. Similarly, DES thrombosis 
mostly occurs in 30 days, but in DES, stent thrombosis risk continues up to 5 years. Because of 
the delayed endothelialization and promoted inflammation, very late stent thrombosis more 
likely seen in DES rather than BMS. Despite all of these, the first generation of DES such as 
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paclitaxel—eluting stent, sirolimus—eluting stent is effective and reliable in use compared 
with BMS.
In the Swedish Coronary Angiography and Angioplasty Registry (SCAAR), 42,150 individu-
als underwent PCI with either BMS or DES. During 661-day follow-up, the rate of described 
stent thrombosis was 1.2%, and half of this was acute and subacute. The rates after the fol-
lowing year decrease to 0.3–0.4% per year constantly up to 3 years. First 6 months after stent 
implantation and onward, the risk for stent thrombosis was higher in DES compared with 
BMS (adjusted risk ratio, 2.02; 99% CI, 1.30–3.14). DES compared with BMS, initially, BMS 
demonstrated a higher risk of stent thrombosis, after the first months, stent thrombosis risk 
was higher with DES [6]. In the Bern-Rotterdam registry, the annual rate of stent thrombo-
sis was 0.4–0.6% for up to 4 years in an 8146 patients who underwent percutaneous coro-
nary interventions with either sirolimus-eluting stent or paclitaxel-eluting stent. Diabetes 
is an independent predictor of early stent thrombosis, whereas acute coronary syndrome, 
younger age, and paclitaxel-eluting stent implantation are associated with late stent throm-
bosis [7]. Use of new generation DES has significantly lower risk of restenosis and stent 
thrombosis though; triggers chronic vessel inflammation, fibrin deposition and cause medial 
cell loss, delay stent strut endothelialization therefore increase the risk of very late stent 
thrombosis [8].
Second-generation DES developed with more bioabsorbable and biocompatible polymers 
and thinner strut stent platforms, which reduce chronic inflammation similar with BMS but 
more effective than BMS also safer than first-generation DES with lower risk of late and very 
late stent thrombosis. The most recent innovation in stent technology was third generation 
bioabsorbable stents that after implantation polymers gradually degraded. Bioabsorbable 
stents are expensive in comparison with DES. In a meta-analysis of Palmerini et al. [9], data 
from 89 trials including 85,490 patients were analyzed. Bioabsorbable polymer-based stents 
were associated with superior clinical outcomes compared with BMS and first-generation 
DES and similar outcomes of cardiac death/MI, target vessel revascularization compared with 
second-generation DES. Real-world studies suggested an increased risk of mortality, MI and 
late stent thrombosis with first-generation DES compared to BMS, especially after discontinu-
ation of dual antiplatelet therapy [10].
Bioresorbable stents with completely absorbable materials have some benefits over BMS and 
DES. These novel stents resolve the shortcoming of DES by enabling re-stent implantation to 
same region and restoration of vasomotor activity. Bioresorbable stents are associated with 
low revascularization rates which also have better short-term outcomes when compared with 
metallic stent technology. As there is a complete bioabsorbtion without any remnant material, 
late and very late stent thrombosis will be significantly less seen. Bioresorbable scaffolds liber-
ate vessel walls from metallic stent material, therefore decrease late remodeling and luminal 
enlargement and save the vessels biomechanics property. Earlier complete resorption allows 
shortening dual antiplatelet treatment duration [11].
In a meta-analysis, 3738 patients in six trials underwent percutaneous coronary intervention 
with either everolimus-eluting bioresorbable vascular scaffold (n = 2337) or everolimus-elut-
ing metallic stent (n = 1401) were included. Patients receiving bioresorbable vascular scaffolds 
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had a similar risk of target lesion revascularization (OR, 0.97 [95% CI, 0.66–1.43]; p = 0.87), 
target lesion failure (1.20 [0.90–1.60]; p = 0.21), MI (1.36 [0.98–1.89]; p = 0.06), and death (0.95 
[0.45–2.00]; p = 0.89) when compared with metallic stent receivers. Bioresorbable vascular 
scaffold implanted group had a higher risk of stent thrombosis than metallic stent group 
(OR, 1.99 [95% CI, 1.00–3.98]; p = 0.05). The highest risk was between 1 and 30 days after 
 implantation (3.11 [1.24–7.82]; p = 0.02). Bioresorbable scaffolds had similar rates necessity of 
revascularization; however, subacute stent thrombosis risk had increased [12].
Stent thrombosis is a main problem as a completely risk of MI and high fatality rates that has 
been stated almost 45%. After a stent implantation, dual antiplatelet therapy is prescribed 
as a routine in the following year. With the use of dual antiplatelet therapy, stent thrombo-
sis declined approximately 1% but can be higher after stenting emergency cases or complex 
lesions [3]. Clinical, procedural, and lesion specific factors induce the development of stent 
thrombosis. Premature withdrawal of dual antiplatelet therapy still constitutes the majority 
[13]. Beside patients noncompliance, clopidogrel or acetylsalicylic acid resistance and hyper-
coagulation disorders predispose to its development. Further risk factors about clinical con-
tain diabetes mellitus, congestive heart failure, renal failure, implantation during acute MI, 
previous brachytherapy. Lesion specific factors are long lesions, smaller vessels, multivessel 
disease, and bifurcation lesions. Persistent dissection, stent underexpansion, incomplete wall 
apposition, multiple stenting, overlapping stents, crush technique, residual flow defect, and 
sort of polymer materials are described as procedure-related risk factors [14].
1.2. Prevention of devastating effects of stent thrombosis
Aspirin and thienopyridines are anti-platelet agents and have different mechanism of action. 
They acquire extensive impact, and combination of both is essential to prevent stent throm-
bosis. Thienopyridine derivates cause platelet inhibition through the P2Y12 ADP receptor 
whose role is to activate the glycoprotein IIb/IIIa complex. Aspirin cause an irreversible cyclo-
oxygenase inhibiting effect and restrains synthesis of thromboxane A2.
In thrombus formation, platelets play critical role, and thus, an optimal dual antiplatelet 
therapy is essential preventing stent thrombosis [15]. Coating stents with cytotoxic material 
and polymers inhibit endothelialization, inflammation in vessel wall, and preliminary tissue 
factor activity. Nowadays, a pro-healing modality has been developed to achieve a natural 
cover of endothelium on stent surface by endothelial progenitor cells. A new approach is 
coating stents label with controlled releasing nitric oxide (NO) for the suppression or pre-
vention of restenosis and thrombosis caused by implantation. NO containing liposomes con-
trol the releasing rate and prolong up to 5 days. In vitro cell studies, point NO enhances 
endothelial cell proliferation, while it significantly inhibits smooth muscle cell proliferation. 
NO-releasing stents with highly optimized release rate demonstrate improvement in arterial 
healing, inflammation, and neointimal thickening except thrombo-resistant effect [16].
CD133 and CD34 antibodies may be able to prevent thrombosis by promoting endothelial 
progenitor cells and accelerating endothelialization. The studies on novel coating strategy 
found that the stainless steel stents coated with vascular endothelial growth factor (VEGF) 
and anti-CD34 antibody less toxic on endothelial progenitor cells than single VEGF coating 
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or bare metals [17]. Anti-CD133 antibody-coated stents have superiority in capturing endo-
thelial progenitor cells and accelerate re-endothelialization when compared with anti-CD34 
[18]. Furthermore, usage of novel biodegradable stents might also contribute the effort given 
against the stent thrombosis [15].
In a multicenter retrospective observational study, among 2047 STEMI patients, 1123 (54.9%) 
of them were received post-procedural bivalirudin full dose infusion, while the other 924 
(45.1%) received low does (0.25 mg/kg/h) or null post-procedural infusion. Three acute stent 
thrombosis (0.3%) occurred in the group of none or low dose bivalirudin, while there was not 
any in the full-dose receiving group (0.3 vs 0.0%, P = 0.092). Full-dose bivalirudin infusion 
after PTCA procedure is safe and has protective effect against acute stent thrombosis [19].
1.3. Cardiogenic shock caused by stent thrombosis: definition, symptoms, predictors, and 
therapy
Cardiogenic shock is characterized by decreased end-organ perfusion due to cardiac dysfunc-
tion, and it is often caused by acute MI which may cause extensive damage of left ventricular 
myocardium or other mechanical complications such as free wall rupture, ventricular septal 
rupture, and papillary muscle rupture. It is a serious disorder with high mortality, aggressive 
and accurate approach increases the likelihood of treatment. The pathophysiological mecha-
nism involves a vicious circle: ischemia causes myocardial dysfunction, which in turn aggra-
vates myocardial ischemia (Figure 1). Cardiogenic shock contains three parameters: persistent 
hypotension (systolic blood pressure <80–90 mm Hg or mean arterial pressure <30 mm Hg) 
with severe reduction in cardiac index (<1.8 L min−1 m−2 without support or <2.0–2.2 L min−1 
m−2 with support) and sufficient or elevated filling pressure (egg, left ventricular end-dia-
stolic pressure > 18 mm Hg, or right ventricular end-diastolic pressure >10–15 mm Hg) [20]. 
Figure 1. Vicious circle in cardiogenic shock.
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Acute MI due to stent thrombosis may lead cardiogenic shock with severe ventricular dys-
function (Figure 2). Early revascularization such as thrombus aspiration with thrombectomy 
catheter and PTCA plays key role to improve the survival (Figure 3 and 4A–F).
1.4. Patophysiology of cardiogenic shock due to stent thrombosis
Stent thrombosis occurs as a result of variety of factors inducing thrombogenesis, clinical, 
and anatomical variability. BMS complete endothelization nearly 3–4 months, this returns 
with risk reduction of stent thrombosis. Antineoplastic stent material, hypersensitivity reac-
tion, inflammatory response, and delayed endothelialization facilitate the risk of stent throm-
bosis in DES. Endothelial cells in the vessel lumen maintain vascular flow with providing a 
barrier to avoid aggregation and coagulation. The most frequent reason is early discontinu-
ation of antiplatelet therapy. Mechanical factors, factors effecting coagulation cascade and 
response to medication, influence the risk of stent thrombosis. Evolution of intracoronary 
thrombus especially in acute coronary syndrome cases is related to high risk of stent throm-
bosis. Stent placement at injury sides increases the platelet deposition. At initial phase, the 
stent side covered with a thin highly platelet rich thrombus label. The neo-intimal structure 
mainly contains smooth muscle cells, and this occurs nearly in 6 weeks and may continue up 
to 12 weeks. In thrombus lesions, the elastic lamina layer is significantly thicker especially 
in plaque and stent area. Also, eosinophil density is apparently higher when compared to 
other lesions without stent [15]. Stent thrombus often ends off with ST elevation MI that 
can easily ruin the contraction of extensive myocardial tissue. This sudden power dissipa-
tion may break the hemodynamic stability and cause deep hypotension. As a vicious circle, 
hypotension reduces the coronary perfusion and enhances ischemia that result with hemo-
dynamic collapse. Also, mechanical complications aggravate and facilitate clinical deterio-
ration. Myocardial stunning and hibernating augment myocardial dysfunction. Increased 
ischemia leads the release of inflammatory mediators like interleukine-6 and cytokines thus 
brings barrier injuries and disrupts microcirculation. Low pressures of blood in vessels initi-
ate multiple organ failure [20].
1.5. Cardiogenic shock caused by stent thrombosis: treatment and literature review
Thrombus aspiration has been associated with retrieving dense thrombus load away from coro-
nary arterials to preserve myocardial performance by enhancing epicardial and microvascular 
Figure 2. Ventricular fibrillation due to acute stent thrombosis. Successful defibrillation made in this patient (arrow).
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Figure 3. A. Total occlusion in Cx (arrow). B. Occlusion was passed with a guidewire (arrow). C. A coronary balloon was 
inflated in the occluded segment (arrow). D. The stent was implanted (arrow). E. The occluded segment was opened. F. 
Acute stent thrombosis of Cx stent (arrow). G. Occlusion was passed with a guidewire (arrow). H. Thrombus aspiration 
with thrombectomy catheter (arrow). I. Flow was reenabled. J, K. A coronary balloon was inflated in the stent. L, M. The 
stent was reopened. LMCA: left main coronary artery, LAD: left anterior descending coronary artery, Cx: circumflex 
artery.
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Figure 4. A, B. Total occlusion in stent (acute stent thrombosis) of mid-portion of left anterior descending coronary 
artery (arrow). LMCA: left main coronary artery, LAD: left anterior descending coronary artery, Cx: circumflex artery. 
C. Thrombosis was passed with a guidewire (arrow). D. A coronary balloon was inflated in the thrombosed stent (arrow). 
E, F. The stent was opened (arrows).
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perfusion. A retrospective study systematically reviewed 13 stent thrombosis cases underwent 
angiography between January 2002 and May 2010. Thrombus aspiration performed 51 patients 
and 62 of them received conventional angiography. Distal embolization was significantly lower 
in thrombus aspiration group when compared with conventional PTCA. Mostly aspirated 
thrombus material included platelet and erythrocyte components at histopathologic analysis. 
Mortality rates in thrombus aspiration group lower but not statistically significant when com-
pared with conventional angiography group (9.8 vs. 16% p: 0.351 at 30 days; 12 vs. 21% p: 0.220 
at 1 year) [21].
Neurohormonal and cytokine systems contribute in the pathogenesis and clinical progress. 
As a result of hemodynamic abnormalities, hypoperfusion symptoms such as mental abnor-
malities, oliguria, anuria, and cool extremites can be seen. Mortality rates are between 10 and 
80%, changes with demographic, initial clinical status, and hemodynamic factors. Early revas-
cularization has a significant effect on survey [20, 22]. In the Arbeitsgemeinschaft Leitende 
Kardiologische Krankenhausarzte (ALKK) registry, in-hospital mortality of patients with 
acute myocardial infarction complicated by cardiogenic shock remained high, especially 
younger patient early invasive approach was the best strategy; however, in elderly patients 
are still a matter of debate [23].
National Cardiovascular Data Registry (NCDR) trial published data from 1,208,137 patients 
PCI procedures performed. In-hospital mortality was 1.4%, ranging from 0.2% within elective 
cases (45.1% of total PCI) to 65.9% among patients with shock and recent cardiac arrest (0.2% 
of total cases). Cardiogenic shock and emergent cases constitute the most predictive inpatient 
mortality. Intervention to chronic total occlusions, stent thrombosis, and left main lesions 
were the angiographic predictors of mortality [24].
Left ventricular ejection fraction (LVEF) is a prognostic indicator in cardiogenic shock. Picard 
et al. [25] performed echocardiography to 175 cardiogenic shock patients, 169 of them were 
suitable for analysis. Patients randomized into two arms: early revascularization or initial 
medical stabilization. In terms of echocardiography, two groups were similar. Mean LVEF 
was 31%, and moderate or greater mitral regurgitation was noted in 39.1%. Both short- and 
long-term mortality estimation according to echocardiographic indicators associated with ini-
tial left ventricular systolic function and mitral regurgitation.
Pulmonary arterial catheterization (PAC) is occasionally performed to confirm the diagnosis 
of cardiogenic shock. In hypotensive cases, clinical assessment of catheterization more reli-
able than echocardiography [26]. Performing pulmonary arterial catheterization was associ-
ated with lower short-term mortality [hazard ratio (HR) = 0.55, 95% confidence interval (CI), 
0.35–0.86, p = 0.008] as well as lower mortality rates in the long-term follow-up (HR = 0.63, 
95% CI 0.41–0.97, p = 0.035). However, according to subgroup analysis, the use of PAC has 
benefits in patients without acute coronary syndrome [26].
The main treatment to deal with cardiogenic shock is early revascularization. Patient’s risk 
factors should be evaluated and closely followed up in case of any impending situation 
especially high heart rate and low blood pressure. Hypoperfusion induces catecholaminer-
gic release but catecholamines increase myocardial oxygen demand so ischemia that causes 
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vicious circle. Using inotropic agents temporarily increase the cardiac output therewith 
peripheral perfusion but unfortunately cannot interrupt the vicious circle. Intra-aortic bal-
loon pump is a temporary solution, improves circulation, peripheral perfusion, and relieve 
ischemia; however, this is not long-term complete solution. Calcium-sensitizing agents such 
as levosimendan have some beneficial effects including positive inotropy, increases in tissue 
perfusion, and anti-stunning and anti-inflammatory effects. In clinical trials, levosimendan 
improves symptoms, cardiac function, hemodynamics, and end-organ function [27].
The Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock 
(SHOCK) trial enrolled 302 patients presented with cardiogenic shock due to left ventricu-
lar failure complicating MI. Patients were randomized in emergency revascularization (152 
patients) or initial medical stabilization (150 patients) groups. Intra-aortic balloon counter-
pulsation was performed 86% patients. At 30 days, there was not any significant difference 
between revascularization and medical therapy groups (46.7 and 56%, respectively; p = 0.11). 
In revascularization group, the mortality rates were significantly lower than medication 
group at 6-month follow-ups (50.3 vs. 63.1%, respectively; p = 0,027). Interventional cardiolo-
gist should strongly considered early revascularization for the patients with MI complicated 
by cardiogenic shock [28].
Stent thrombosis is a rare disorder while depending on the extensity of ischemic surface, 
cardiogenic shock can be occur with ventricular dysfunction and become life-threatening. 
Cardiogenic shock mainly associated with the infarct-related territories. A study observed 92 
ST segment elevated patients from January 2004 to March 2007 [29]. Of the total, 15.2% (n = 14) 
presented with cardiogenic shock and 85.7% (n = 12) were DES thrombosis. Coronary collat-
eral growth is injured with DES which inhibits formation of cytokines, chemotactic proteins, 
and proliferation of vascular smooth muscle cells. Mean time passed from stent implantation 
procedure to stent thrombosis was 4.5 ± 7.6 months. 57% of the stent thrombosis occurred less 
than 30 days (early stent thrombosis). In 35.7% cases, MI related to left main or multivessel 
stent thrombosis. Before coronary angiography, all patients underwent intra-aortic balloon 
pump implantation [enlarges during diastole, prior to systole, and the balloon is deflated. 
Therefore, device augments diastolic pressure, reduces afterload, enhances coronary perfu-
sion, and improves cardiac output [30]. In 80% of cases, revascularization was achieved, and 
21% of cases, Impella LP 2.5 pump was used because of the low cardiac output persistence. 
In-hospital survival was 28.6%, and in the majority of cases, death occurred within the first 
48 h. All the patients who survived in the acute phase were alive at 6 months visit and had sig-
nificantly lower thrombus grade after wire passage (p = 0.03). However, they showed a higher 
rate of very late stent thrombosis, longer times from symptoms onset to revascularization, and 
higher TIMI flow grade both before and after percutaneous coronary intervention [29].
The IMPRESS trial compares the 30-day mortality rates of Impella CP and intra-aortic bal-
loon pump devices in patients with severe shock complicating acute MI. Forty eight patients 
randomized to Impella CP (n = 24) or intra-aortic balloon pump (n = 24). At 30 days, mortality 
in patients treated with either intra-aortic balloon pump or Impella CP was similar (50 and 
46%, respectively, p = 0.92). At 6 months, mortality rates for both Impella CP and intra-aortic 
balloon pump were 50% (p = 0.923) [31].
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Mechanical circulatory support device implantation when in early cardiogenic shock mani-
festation, before inotropic and vasopressor agents or coronary intervention, is independently 
associated with decreased mortality rates. An immediate and adequate device assists cardiac 
support especially Impella or intra-aortic balloon pump and supplies reperfusion without 
any delay are the key points of improving survival of these patients under high risk [29].
Therapeutic hypothermia is beneficial of care after cardiac arrest. ISAR-SHOCK registry 
included 145 patients with acute MI, cardiogenic shock, and primary percutaneous coronary 
intervention, 64 (44%) patients received therapeutic hypothermia treatment. After 30-day fol-
low-up, no significant differences were observed between both groups for mortality (42 vs. 44%, 
HR: 0.93, 95% CI [0.56–1.53], p = 0.77) and MI (6 vs. 6%, HR: 0.99 95% CI [0.27–3.7], p = 0.99). 
Three definite stent thrombosis were observed, and all of them belonged to therapeutic hypo-
thermia group (p = 0.09). Therapeutic hypothermia does not have a negative effect in patients 
who receives clopidogrel or prasugrel [32].
2. Conclusion
Stent thrombosis is the nightmare of interventional cardiologists with fatal complications 
such as cardiogenic shock. It occurs rarely but has significantly high incidence of in-hospital 
mortality. Primary strategy should avoid all the predisposing factors. The main reason of 
cardiogenic shock due to stent thrombosis is extensiveness of infarct-related myocardial tis-
sue. Early revascularization and intensive life support to supply cardiac output with inotropic 
agents and/or mechanical circulatory devices are the beneficial strategies.
3. In the future
Developments in stent technology and novel drugs inhibits platelet aggregation are decreasing 
the complications of stent implantation. By completely absorption of stent material in novel 
stents, dual anti-platelet therapy shortens and overall late stent thrombosis and revasculariza-
tion rates decreases. Recently, endothelial progenitor cell-capturing stent technology contrib-
utes re-endothelialization. With the improvement in therapeutic modulations, incidences of 
cardiogenic shock due to stent thrombosis and mortality rates are in decreasing tendency.
4. Take home messages
• Choice of stent type depends on clinical properties, patient and angiographic features, and 
carries significant weight.
• Appropriate use of dual anti-platelet therapy is essential and should be explained to pa-
tient carefully.
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• In case of any cardiogenic shock presentation, patient should promptly transport to cath-
eterization laboratory for urgent revascularization.
• Revascularization is the keystone of cardiogenic shock management due to stent 
thrombosis.
• To maintain end organ perfusion, inotropic agents and mechanical circulatory support de-
vices are the only bullets for surviving from cardiogenic shock.
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